Recent Posts
Blog Post
04/26/2022
By Jonathan A. Havens and Seth Gitner

Adult use of cannabis is currently authorized in Washington D.C. (D.C. or the District),1 but due to a congressional rider preventing the District from using any funds to enact and regulate a legal market, an unregulated marketplace has thrived, operating under the premise that retailers cannot sell, but can “gift” cannabis to consumers.  The success of the largely unregulated D.C. adult-use market has given political capital to these “gifting” retailers, thwarting the D.C. Council’s most recent efforts at reform.

Blog Post
04/15/2022
By Adam Fayne and Jonathan A. Havens and Ruth A. Rauls and Matthew J. Smith

On Thursday, April 14th, New Jersey’s Cannabis Regulatory Commission (“CRC” or the “Commission”) announced that adult-use (i.e., recreational) cannabis sales can begin in the Garden State at certain dispensaries on April 21, 2022.

Blog Post
04/16/2021
By Jonathan A. Havens and Ruth A. Rauls and Matthew J. Smith

New Jersey’s Cannabis Regulatory Commission (CRC) has been fully appointed and held its first meeting on April 12, 2021. Now it gets to work on setting up all aspects of New Jersey’s newly created adult-use market and overseeing New Jersey’s existing medical cannabis program. This includes, among other things, issuing regulations and handling all aspects of licensing and permitting. Read our cannabis group's most recent alert inside.

Blog Post
12/23/2020
By Ruth A. Rauls

Throughout 2020, Pennsylvania courts issued a series of decisions clarifying employee rights for medical cannabis patients—one related to unemployment compensation and others related to private rights of action under its medical cannabis statute, the Medical Marijuana Act (“MMA”). Under the MMA, individuals with serious medical conditions who may benefit from the use of medical marijuana can obtain prescriptions for it from licensed healthcare providers. Most recently, in Pittsburgh Water and Sewer Authority v. Unemployment Compensation Board of Review, the Pennsylvania Commonwealth Court affirmed a decision by the Unemployment Compensation (“UC”) Board of Review — finding that a former employee who was lawfully using medical marijuana pursuant to the MMA was entitled to UC benefits following termination for a positive drug test. Additionally, both Pennsylvania state and federal courts have issued decisions regarding what type of claims a medical cannabis patient can assert, and under which statute those claims can be asserted.

Blog Post
12/21/2020
By Jonathan A. Havens

On December 18, 2020, just three days after the U.S. Senate adopted the Cannabidiol and Marihuana Research Expansion Act (CMREA or the Act), the U.S. Drug Enforcement Administration (DEA or the Administration) published in the Federal Register a final rule, “Controls To Enhance the Cultivation of Marihuana for Research in the United States” (Rule), which finally paves the way for DEA to issue additional licenses to grow “marihuana” (i.e., cannabis) for research purposes.

Blog Post
12/18/2020
By Jonathan A. Havens

On December 17, 2020, the Federal Trade Commission (FTC or the Commission) announced that it has taken action against six cannabidiol (CBD) brands for allegedly making a wide range of unsubstantiated claims about the ability of the firms’ products to treat serious health conditions (e.g., cancer, heart disease, hypertension, Alzheimer’s disease).  FTC is calling its enforcement sweep “Operation CBDeceit.”

Pages